Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | MC5R | P33032 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80282 | 0.94 | SIGMAR1 (0.59) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL9672316 | 0.89 | SIGMAR1 (0.47) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL9129308 | 0.88 | SIGMAR1 (0.58) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL19116113 | 0.88 | TDP1 (0.50) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL8422096 | 0.86 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL31036062 | 0.86 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL7621730 | 0.86 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL9588844 | 0.86 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL314040 | 0.81 | CYP1A2 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL30985268 | 0.81 | CYP1A2 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0604409-B1 | OLIGONUCLEOTIDE ANALOGS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1418179-A2 | Compositions and methods for detecting and modulating rna activity and gene expression | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6262241-B1 | ANTISENSE COMPOUNDS WHICH CLEAVE PHOSPHORODIESTER BONDS AND IMPROVE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF OLIGONUCLEOTIDES, USEFUL IN DIAGNOSING DISEASES | ISIS PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-5948903-A | Synthesis of 3-deazapurines | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5750692-A | Synthesis of 3-deazapurines | ISIS PHARMACEUTICALS, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5587470-A | 3-deazapurines | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0604409-A4 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION. | ISIS PHARMACEUTICALS INC (US) | 1996-06-12 | — | — | EP | disclosed |
| US-5457191-A | 3-deazapurines | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0604409-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |